Table 1:
Demographic and clinicopathological characteristics of NAT cohort.
| Patient Characteristics | PDO Established Success (n=11) |
PDO Establishment Failure (n=7) |
p value |
|---|---|---|---|
| Age, yrs median (IQR) | 70 (62–75) | 61 (54–73) | 0.3335 |
| Sex (female), n % | (5) 45% | (4) 57% | 0.783 |
| AJCC Stage 8th edition I/II III IV |
5 3 3 |
1 6 0 |
0.17 |
| Surgical Stagea Resectable Borderline Resectable Locally Advanced Oligometastatic |
2 3 3 3 |
2 2 3 0 |
0.488 |
| Pretreatment CA 19–9 units, median (IQR) | 260 (214–1482) | 919 (500–1964) | 0.153 |
| Pretreatment Tumor size by CT (mm), median (IQR) | 25.5 (21.75–37.25) | 41 (30–53) | 0.153 |
| First line of NAT - FFX (n)% | (6) 54% | (4) 57% | 0.732 |
| First line of NAT- GnP (n)% | (4)36% | (3) 43% | 0.732 |
| Total number of NAT doses | 7 (3–9) | 8 (8–12) | 1 |
| NAT Radiation (n) % | (1) 9% | (7) 100% | <0.001 |
| Preoperative CA 19–9 units, median (IQR) | 50 (35–444) | 159 (125–590) | 0.132 |
| Preoperative Tumor size by CT (mm), median (IQR) | 18.5 (18–313.5) | 24 (23–44) | 0.3350 |
| Primary tumor cellularity % based on pathology histology, median (IQR)b | 73 (39–86) | 65 (44–76) | 1 |
| Pathological NAT responsec Grade 2 Grade 3 |
(6) 55% (5) 45% |
(5) 71% (2) 29% |
0.474 0.476 |
| Grade of tumor differentiation Grade 1 Grade 2 Grade 3 |
0 (9) 82% (2) 18% |
(1) 14% (4) 57% (2) 28% |
0.197 0.255 0.605 |
| Tumor size on path | 25 (23–35) | 35 (31–44) | 0.335 |
Abbreviations: PDO, patient-derived organoids; mFFX, modified FOFIRINOX; GnP, gemcitabine/abraxane; NAT, neoadjuvant chemotherapy
b
Tumor Cellularity (%) score was calculated as the number of histology slides with viable adenocarcinoma divided by the total number of slides sampled from the resected tumor.
c
According CAP protocol3